Inovio Pharmaceuticals: HC Wainwright Raises PT to $3 from $3, Maintains Neutral Rating.

Inovio Pharmaceuticals: HC Wainwright Raises PT to $3 from $3, Maintains Neutral Rating.

Inovio Pharmaceuticals (NASDAQ: INO) experienced a notable shift in analyst sentiment with HC Wainwright & Co. maintaining its Neutral rating while raising the price target (PT) to $3 from $3. This move follows the company's recent financial performance and strategic advancements.

Inovio reported a significant reduction in net losses for the second quarter of 2025, with operating expenses down by 31% and net loss per share cut by nearly half. The company's shares experienced a 2.43% increase in aftermarket trading following the announcement, reflecting investor optimism. Despite these positive developments, the stock has been volatile, with analysts predicting varying outcomes based on the latest clinical data.

The company is focusing on its Biologics License Application (BLA) submission for INO-3107, expected in the second half of 2025, with a potential priority review that could lead to a PDUFA date in 2026. Inovio is also exploring a redosing strategy for long-term treatment and continues to develop its pipeline in DNA-encoded monoclonal antibodies and cancer prevention.

The market reaction to Inovio's Q2 2025 results demonstrates a strategic focus on reducing losses and advancing key product developments. The company's efforts in regulatory submissions and market preparation are pivotal as it seeks to establish a stronger foothold in the biotechnology sector.

References:
[1] https://www.ainvest.com/news/inovio-pharmaceuticals-q2-results-net-loss-narrows-0-61-share-2508/
[2] https://www.ainvest.com/news/major-earnings-expected-close-tuesday-coreweave-inovio-pharmaceuticals-luminar-technologies-2508/
[3] https://finance.yahoo.com/quote/INO/analysis/
[4] https://ca.investing.com/news/analyst-ratings/jmp-analyst-reiterates-market-outperform-rating-on-inovio-stock-93CH-4154510